Table 3a Response to VYTORIN and Atorvastatin in Patients with Primary Hypercholesterolaemia Percent Change from Untreated Baselineb) Treatment Total-C TGa Non-HDL-C Pct† LDL-C Pct† B Pct† HDL-C Pct† Pct† Pct† (Daily Dose) N [Baseline‡] [Baseline‡] [Baseline‡] [Baseline‡] [Baseline‡] [Baseline‡] Pooled data (All VYTORIN 951 -38c -53c -43c +8c -27 -49c doses) [6.83] [4.60] [1.65] [1.27] [1.93] [5.56] Pooled data (All atorvastatin 951 -34 -45 -38 +4 -26 -42 [6.84] [4.63] [1.65] [1.26] [1.89] [5.58] VYTORIN by dose -34d -47d -37d +8 -26 -43d 10/10 238 [6.83] [4.57] [1.65] [1.27] [1.96] [5.56] 10/20 238 -37d -51d -40d +7 -25 -46d [6.84] [4.62] [1.64] [1.27] [1.89] [5.57] 10/40 238 -41d -57d -46d +9d -27 -52d [6.85] [4.60 [1.66] [1.27] [1.94] [5.58]
Table 3a Response to VYTORIN and Atorvastatin in Patients with Primary Hypercholesterolaemia Percent Change from Untreated Baselineb) Treatment (Daily Dose) N Total-C Pct† [Baseline‡] LDL-C Pct† [Baseline‡] B Pct† [Baseline‡] HDL-C Pct† [Baseline‡] TGa Pct† [Baseline‡] Non-HDL-C Pct† [Baseline‡] Pooled data (All VYTORIN doses) 951 -38c [6.83] -53c [4.60] -43c [1.65] +8c [1.27] -27 [1.93] -49c [5.56] Pooled data (All atorvastatin 951 -34 [6.84] -45 [4.63] -38 [1.65] +4 [1.26] -26 [1.89] -42 [5.58] VYTORIN by dose 10/10 238 -34d [6.83] -47d [4.57] -37d [1.65] +8 [1.27] -26 [1.96] -43d [5.56] 10/20 238 -37d [6.84] -51d [4.62] -40d [1.64] +7 [1.27] -25 [1.89] -46d [5.57] 10/40 238 -41d [6.85] -57d [4.60 -46d [1.66] +9d [1.27] -27 [1.94] -52d [5.58]